Grace Halsey

AAAAI Virtual Annual Meeting. Two-thirds of severe asthma patients dependent upon oral corticosteroids stopped or maximally reduced use, according to the trial data.

Post-COVID-19 health care delivery will depend, in part, on patient preference and lingering concerns. New research identifies 4 patient groups with divergent feelings.

Cannabis researchers Drs Carrie Cuttler and Rebecca Craft discuss their findings, their labs at WSU, their new research, and what makes this kind of research a challenge.

As states implement the CDC ACIP's COVID-19 vaccination priorities, they are revising them as needed based on federal, state, and local conditions. Here is a recent snapshot.

FDA approved the fixed-dose combination heart failure drug sacubitril/valsartan to reduce risk of CV death and hospitalization in patients with chronic heart failure.

To ensure COVID-19 vaccination priority for the sickest CVD patients, the ACC statement identifies highest risk conditions within CVD to aid clinician decision making.

As a group, Americans who want to wait and see how the COVID-19 vaccine works for others are younger and more diverse than those who want it ASAP.

Authors of 2 large cannabis-user database analyses discuss the possible reasons for observed dose increase over time by individuals using inhaled cannabis for pain relief.

In animal models, pain relief from cannabis has been found to be greater in females; new research on pain relief from inhaled cannabis in regular users found something different.

A new survey of patients with asthma who use cannabis finds smoking and vaping preferred routes and that physicians rarely inquire about marijuana use.

Research on pain relief from use of medical cannabis poses myriad challenges. Veteran researchers discuss 2 new studies based on a deep well of user data.

In the state with the highest COVID-19 death rate, 1 in every 406 residents has died; in the state with the lowest rate, the number is 1 in every 3436. Which states are they?

Variability in A1c during the first 2 years after T2D diagnosis is a strong predictor of CV disease; study authors note the risk may be mediated by severe hypoglycemic episodes.

Heart disease, again the leading cause of death worldwide, may remain so for many years as a result of COVID-19 pandemic conditions, says AHA Update Writing Committee Chair.

Kaiser Family Foundation: New data from 23 states show consistently smaller shares of vaccination among Blacks vs Whites based on share of cases and deaths and of total population.

Antidepressants, although guideline-recommended and widely prescribed for common pain conditions, may not be as effective as perceived. Author of a new meta-analysis explains.

Oxford researchers will evaluate the interchangeability of the vaccines, the impact of different dosing intervals, and the potential for enhanced immune response.

Video: George Bakris, MD says over the next 3 years there is going to be an "explosion" in the number of studies we see in heart failure, diabetic kidney disease, and CV risk in general.

Hyaluronan represents a new class of biologic that significantly improves lung health in patients with severe COPD.

Opioids or opiate-like analgesics? Weight loss, exercise, or orthotics? Sleep interventions or cognitive therapy? What works for OA pain and what's the evidence?

Patients most often blame forgetfulness for not getting a second shot so reminders are key; just don't rely on a message via a patient portal to reach them.

Director of the Brigham and Women's Diabetes Program Marie McDonnell, MD, talked with our editor about 2020 studies on SGLT-2 inhibitors, insulin icodec, and more.

Vaccines from both companies were significantly effective against COVID-19 and show promise against variants from the UK and South Africa.

In a phase 2/3 study, nearly half of rimegepant-treated patients demonstrated ≥50% reduction in the number of moderate-to-severe migraine days per month

The FDA approved vericiguat to reduce the risk of CV death and rehospitalization for HF in HF patients after hospital discharge or after outpatient treatment with IV diuretics.

The COVID-19 pandemic, says Dr Michael Myers, is an unprecedented environment for practicing medicine and for practitioners to effectively process daily experience.

Availability of the COVID-19 vaccine cannot come fast enough for many large US cities, based on the share in each of the most vulnerable populations.

Physical activity cannot compensate adequately for the negative impact of excess body weight on cardiometabolic health.

Cabotegravir and rilpivirine, injectable formulation is administered once-weekly, reducing treatment days for adults with HIV from 365 to 12.

The FDA provides details on how COVID-19 infection or vaccination against the virus affects a waiting period to donate. Please share the information with your patients.